Metagil-GP2

Composition: Glimepiride 2 mg + Metformin 500 mg + Pioglitazone 15 mg (Sustained Release)

Metagil GP-2 is a triple-combination anti-diabetic medication designed for patients requiring stronger and well-rounded blood sugar control. It contains Glimepiride (which boosts insulin secretion), Metformin (which reduces liver glucose output and improves insulin sensitivity), and Pioglitazone SR (which enhances the body’s response to insulin throughout the day). This powerful combination helps control fasting sugar, post-meal sugar, and HbA1c more effectively than dual therapy. Metagil GP-2 is ideal for patients with long-standing diabetes or those with insulin resistance.

Uses:

• Management of Type 2 Diabetes Mellitus
• Effective reduction of HbA1c
• Control of fasting and postprandial blood sugar
• Helps improve insulin sensitivity
• Suitable when dual therapy is insufficient

Side Effects:

• Hypoglycemia
• Weight gain or swelling
• Dizziness or headache
• Stomach upset or diarrhea
• Fluid retention (Pioglitazone-related)
• Rare: risk of lactic acidosis

Other Details:

• Best taken with food
• Not advisable for patients with heart failure or severe kidney issues
• Regular monitoring of blood sugar and weight is recommended
• Avoid alcohol to reduce risk of lactic acidosis